LUPIN – US Launch & TGA Boost
Two big moves caught my attention: they got approval to sell drug ingredients (APIs) globally through Australia's regulator, and launched Tolvaptan in the US - a specialty drug that could bring in $200 million over the next couple years.
Instead of just making copycat pills that get cheaper every year, Lupin's moving into the behind-the-scenes stuff - making the actual ingredients other companies need, and launching more complex drugs with less competition.
The upside is real:
- API business has way better margins than basic generics
- Tolvaptan treats a rare condition, so less pricing pressure
- Global API approval opens doors they couldn't access before
If
